Literature DB >> 24425792

Radiofrequency ablation combined with transcatheter therapy in rabbit VX2 liver tumors: effects and histopathological characteristics.

XuHua Duan1, GuoFeng Zhou2, XinWei Han3, JianZhuang Ren3, ChuanSheng Zheng4, HuiMin Liang4, GanSheng Feng4.   

Abstract

BACKGROUND: Transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) treatment (TACE-RFA) has been confirmed superior to TACE or RFA alone in animal liver tumors. TACE before RFA was shown to increase hepatocellular damage. Further optimization of the combination strategy for transcatheter arterial embolization (TAE) or TACE combined with RFA is warranted.
PURPOSE: To determine the optimal strategy for radiofrequency ablation combined with transcatheter therapies in VX2 liver tumors in a rabbit model.
MATERIAL AND METHODS: Twenty-four Japanese White rabbits with VX2 liver tumors were randomly divided into four groups: TACE-RFA (TACE-RFA group), transcatheter arterial embolization (TAE) combined with RFA treatment (TAE-RFA group), RFA only group, and TACE only group. Blood samples were collected 1 day before the operation and at 3 and 7 days postoperatively. Seven days after the operation, maximal diameters of coagulation or infarcted zones in the gross specimens, CT images, histopathological characteristics, tumor necrotic rate, and growth rate were compared.
RESULTS: Significantly larger mean long-axis (P < 0.05) and short-axis (P < 0.05) diameters of coagulation and infarction were observed in the TACE-RFA group compared with the TAE-RFA, RFA, and TACE groups on day 7; and the TAE-RFA group showed a significant (P < 0.05) increase versus the RFA and TACE groups on day 7. There were no significant differences in tumor growth rate (109.3 ± 37.5 vs. 119.0 ± 43.1%, P = 0.45) and necrotic rate (89.5 ± 12.0 vs. 83.5 ± 9.3%, P = 0.73) between the TACE-RFA and TAE-RFA groups. TACE-RFA was more effective for achieving tumor destruction than the other treatment strategies, but led to increased rabbits discomfort and more severe liver dysfunction compared with TAE-RFA.
CONCLUSION: TAE-RFA appears to be a beneficial therapeutic modality for treating VX2 liver tumors in a rabbit model. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Transcatheter arterial chemoembolization; VX2 liver tumor; radiofrequency ablation; transcatheter arterial embolization

Mesh:

Year:  2014        PMID: 24425792     DOI: 10.1177/0284185113520266

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

Review 1.  Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.

Authors:  Andrew R Lewis; Carlos A Padula; J Mark McKinney; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 2.  Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages.

Authors:  Joseph Titano; Amir Noor; Edward Kim
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

3.  Transcatheter arterial embolization combined with radiofrequency ablation activates CD8(+) T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors.

Authors:  Xu-Hua Duan; Teng-Fei Li; Guo-Feng Zhou; Xin-Wei Han; Chuan-Sheng Zheng; Peng-Fei Chen; Gan-Sheng Feng
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

4.  The influence of liposomal quercetin on liver damage induced by microwave ablation.

Authors:  Xuhua Duan; Pengfei Chen; Xinwei Han; Jianzhuang Ren; Zhaoyang Wang; Guorui Zhao; Hao Li
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

5.  Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors.

Authors:  Shuyi Xiao; Zhiwen Hu; Yan He; Hai Jin; Yuwen Yang; Liping Chen; Qiaoli Chen; Qiong Luo; Jianhua Liu
Journal:  Biomed Res Int       Date:  2020-01-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.